TheraRadar
← Back
Data updated: Mar 29, 2026

GALDERMA LABS LP

DermatologyImmunology
Big Pharma

GALDERMA LABS LP is a major pharmaceutical company focused on Dermatology, Immunology. Key products include MIRVASO.

1984
Since
17
Drugs
-
Trials
7
Approved (2yr)

Key Drugs

MIRVASO
brimonidine tartrate
alpha-2 adrenergic receptor 1 indications · 2013
SOOLANTRA
ivermectin
1 indications · 2014
AKLIEF
trifarotene
RAR-gamma 1 indications · 2019

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Recent Activity

NEMLUVIO 2025-06-26
Labeling
NEMLUVIO 2025-06-26
Labeling
NEMLUVIO 2025-04-21
Labeling
ORACEA 2025-04-02
Labeling
PERIOSTAT 2025-04-01
Labeling
NEMLUVIO 2024-12-13
Type 1 - New Molecular Entity
NEMLUVIO 2024-08-12
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Dermatology 67%
4 drugs
Immunology 33%
2 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Dermatology, Immunology
Eli Lilly big-pharma
Immunology, Dermatology
BAUSCH specialty
Dermatology, Immunology
COSETTE other
Dermatology, Immunology
BAUSCH AND LOMB specialty
Dermatology, Immunology